Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierModerna is a pioneer and leader in the field of mRNA medicine. Through the advancement of our technology platform, we are reimagining how medicines are made to transform how we treat and prevent diseases. Since our founding, our mRNA platform has enabled the development of vaccine and therapeutic candidates across infectious disease, oncology, rare disease and more. With a global team and a unique culture, driven by our values and mindsets, our mission is to deliver the greatest possible impact to people through mRNA medicines.
In the company’s own words · 10-K filed Feb 20, 2026 · SEC EDGAR
Business segments
Q1 2026 · $426.0MThe company’s own SEC segment disclosure.
- COVID19$345.0M81%
- Product And Service Other$37.0M9%
- Stand Ready Manufacturing$32.0M8%
- RSV$7.0M2%
- Collaboration Arrangement Including Arrangements With Affiliate$5.0M1%
Moderna (MRNA) reported revenue of $145M in Q2 2026 (quarter ended June 30, 2026), up 2.1% from the same quarter a year earlier. That came with a gross margin of 36% and net loss of $782M. For the full year FY2025, revenue was $1.94B (−40% year on year) and net income −$2.82B. Its largest product in 2026-Q1 was COVID19 at $345M, 81% of the disclosed total, just ahead of Product And Service Other at 8.7%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Biotechnology
Ranks #30 of 145 by Smart Score